Radioimmunotherapy study of <sup>131</sup>I-labeled Atezolizumab in preclinical models of colorectal cancer.

Authors:
Zhang L; Zhao S; Jiang H; Zhang R; Zhang M and 4 more

Journal:
EJNMMI Res

Publication Year: 2022

DOI:
10.1186/s13550-022-00939-2

PMCID:
PMC9616992

PMID:
36307610

Journal Information

Full Title: EJNMMI Res

Abbreviation: EJNMMI Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Radiology, Nuclear Medicine & Medical Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"additional file 1. fig s1c . the raw data"

Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateAll procedures were performed with the approval of the Institutional Animal Care and Use Committees of Jiangsu Institute of Nuclear Medicine. All methods were carried out in accordance with relevant guidelines and regulations. The study was carried out in compliance with the ARRIVE guidelines. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Funding This study was supported by grants from the National Key Research and Development Program of China (2019YFC0118100); National Natural Science Foundation of China (81671760, 81873910, and 82001860); and Beijing Friendship Hospital Seed Project, Capital Medical University (YYZZ201919)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025